Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

Next Previous
Trial Profile

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EO 2463 (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Montanide ISA-51
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms SIDNEY
  • Sponsors Enterome

Most Recent Events

  • 23 Jun 2025 Interim results presented in a Enterome Media Release.
  • 23 Jun 2025 According to Enterome Media Release, company presented interim data from this study of 24 patients with follicular and marginal zone lymphoma (relapsed/refractory iNHL) from Cohorts 1 and 4 at the International Conference on Malignant Lymphoma (ICML) in Lugano.
  • 12 Jun 2025 According to Enterome Media Release, company raises $19 million to fund this Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top